Study on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma

Sponsor: New York Medical College

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04491370

Provider View

This clinical trial is testing a treatment plan that includes a stem cell transplant followed by the drug Polatuzumab Vedotin for patients with certain types of B-cell Non-Hodgkin and Hodgkin Lymphoma. The study aims to see if this approach can help control the disease.

Patient Parameters

Program Overview

In this study, patients with B-cell Non-Hodgkin and Hodgkin Lymphoma will first receive a stem cell transplant after undergoing one of two pre-treatment regimens. If their cancer shows a complete, partial, or stable response after the transplant, they will then receive Polatuzumab Vedotin through an IV every 21 days for a total of 8 doses. After completing this treatment, patients will have follow-up visits every 4 months for about 2 years to monitor their health and the effectiveness of the treatment.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with specific types of B-cell Non-Hodgkin or Hodgkin Lymphoma, such as Burkitt lymphoma or Diffuse Large B Cell Lymphoma.
  • The cancer must have either not responded to initial treatment or returned after treatment, but shows some response to re-treatment.
  • Must have a performance status score of at least 50%, indicating the ability to carry out daily activities.
  • Expected to live for more than 6 weeks.
  • Must have recovered from any side effects of previous cancer treatments.
  • Must have adequate kidney, liver, heart, and lung function as determined by specific medical tests.
  • Must have a sufficient number of stem cells collected and stored before starting the treatment.
  • Must provide written informed consent to participate in the study.

Exclusion Criteria

  • Cannot have had a previous stem cell transplant.
  • Cannot have active cancer in the central nervous system.
  • Cannot be taking other experimental treatments for B-cell lymphoma.
  • Cannot be pregnant or breastfeeding.
  • Must agree to use effective birth control if sexually active and able to have children.
  • Cannot have an uncontrolled infection.
  • Cannot have severe nerve damage (Grade 3 or higher neuropathy).

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.